BioWorld

Oct. 28, 2005

View Archived Issues

ZymoGenetics Starts Pivotal rhThrombin Phase III Study

Nearly three months after raising $135 million to move its lead blood-clotting agent into a pivotal study, ZymoGenetics Inc. started the Phase III trial of recombinant human Thrombin (rhThrombin) in surgery patients. (BioWorld Today) Read More

NicOx Licenses Respiratory Drug To Topigen For 54.9M

Read More

Antibiotics Developers Report New Compounds, Mechanisms

Read More

Meeting Looks At Financing Matters, Strategies For Exit

Read More

Other News To Note

Read More